Sertraline Hydrochloride Form II is a defined crystalline polymorph of sertraline hydrochloride, the hydrochloride salt of the active pharmaceutical ingredient sertraline. Sertraline belongs to the selective serotonin reuptake inhibitor (SSRI) class and is widely used in pharmaceutical formulations for the management of depression and several anxiety-related and psychiatric disorders.
Sertraline hydrochloride exists in multiple solid-state forms. U.S. patent literature identifies Form I, Form II, Form III, Form IV and Form V, with differences in crystal structure, thermal behavior, physical properties and stability. The material prepared according to the original sertraline hydrochloride synthesis was subsequently identified as polymorphic Form II.
Sertraline Hydrochloride has the chemical formula C17H18Cl3N and molecular weight 342.69 g/mol. The API corresponds to the hydrochloride salt of the (1S-cis) sertraline active moiety.
Key product information:
The Form II designation is particularly important for API control because polymorphic conversion can alter physical characteristics and potentially affect pharmaceutical processing and dissolution behavior. Patent literature describes Form II as a metastable polymorph relative to the more stable Form I.
Sertraline Hydrochloride Form II is a crystalline hydrochloride salt. Its polymorphic identity should be established using an appropriate validated solid-state analytical method rather than relying only on conventional chemical identification.
Powder X-ray diffraction (XRPD) is particularly important for demonstrating the required crystalline form. Other techniques such as infrared spectroscopy, differential scanning calorimetry and, where required, single-crystal X-ray analysis can support polymorphic characterization.
Sertraline is an established SSRI used in pharmaceutical products for conditions including:
The API is incorporated into oral pharmaceutical dosage forms such as tablets, capsules and oral solutions.
Sertraline selectively inhibits the neuronal reuptake of serotonin, increasing serotonergic activity in the central nervous system. Its pharmacological activity is associated with modulation of serotonin neurotransmission.
The hydrochloride salt and crystalline form provide the physical form in which the active pharmaceutical ingredient is manufactured and processed.
Sertraline HCl Form II requires both chemical purity testing and polymorph control.
Important analytical controls include:
The USP monograph establishes numerical requirements for sertraline hydrochloride including assay, residue on ignition, water and impurity controls.
For a Form II-specific API, polymorphic identity should additionally be controlled against an approved Form II reference pattern.
Sertraline Hydrochloride Form II is produced through controlled salt formation and crystallization. Patent literature describes preparation of Form II by crystallizing sertraline hydrochloride from suitable organic solvent systems and controlling crystallization conditions to obtain Form II substantially free of other polymorphs.
Form II manufacturing therefore requires control over solvent system, temperature, seeding, hydrogen chloride addition and crystallization kinetics.
Sertraline Hydrochloride is described as a white to off-white crystalline powder. It is slightly soluble in water and isopropyl alcohol, very slightly soluble in dilute aqueous hydrochloric acid, practically insoluble in dilute sodium hydroxide, sparingly soluble in ethanol and soluble in chloroform.
A melting range of approximately 243–245°C is reported for the sertraline hydrochloride material identified in the patent literature as Form II.
Sertraline Hydrochloride should be protected from moisture and light and maintained in appropriately closed pharmaceutical-grade packaging. The applicable pharmacopoeial or approved API stability specification should determine the final storage conditions.
For Form II specifically, storage conditions are important because patent literature reports that polymorphic conversion can occur under certain processing and stress conditions.
A commercial Sertraline HCl Form II API documentation package may include:
Sertraline Hydrochloride Form II requires control of both chemical quality and crystalline polymorphic form. Consistent crystallization conditions, XRPD verification, impurity control and validated analytical methods are essential for reproducible API quality.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Residue on Ignition | NMT 0.3% |
| Heavy Metals | NMT 30 ppm |
| Individual Impurity | NMT 0.10% |
| Total Impurities | NMT 1.5% |
| Water Content | NMT 0.50% |
| Melting Point | 243–245°C |